BeiGene (FRA:49BA) Other Long-Term Liabilities : €158 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is BeiGene Other Long-Term Liabilities?

BeiGene's other long-term liabilities for the quarter that ended in Dec. 2023 was €158 Mil.

BeiGene's quarterly other long-term liabilities declined from Jun. 2023 (€193 Mil) to Sep. 2023 (€180 Mil) and declined from Sep. 2023 (€180 Mil) to Dec. 2023 (€158 Mil).

BeiGene's annual other long-term liabilities declined from Dec. 2021 (€239 Mil) to Dec. 2022 (€170 Mil) and declined from Dec. 2022 (€170 Mil) to Dec. 2023 (€158 Mil).

BeiGene Other Long-Term Liabilities Historical Data

The historical data trend for BeiGene's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Other Long-Term Liabilities Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

BeiGene Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

BeiGene Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

BeiGene Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of BeiGene's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (FRA:49BA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (FRA:49BA) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

BGNE:USA 06160:Hong Kong 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

BeiGene (FRA:49BA) Headlines

No Headlines